KalVista Pharmaceuticals (KALV) Accumulated Depreciation & Amortization (2014 - 2025)

KalVista Pharmaceuticals has disclosed Accumulated Depreciation & Amortization across 12 years of filings, most recently posting $4.7 million for Q2 2025.

• Accumulated Depreciation & Amortization for Q2 2025 came in at $4.7 million, up 27.88% year-over-year; the trailing twelve-month figure through Apr 2025 was $4.7 million (up 27.88% YoY), and the FY2025 annual result was $4.7 million, up 27.88% from the prior year.
• Accumulated Depreciation & Amortization came in at $4.7 million for Q2 2025 at KalVista Pharmaceuticals, up from $3.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.7 million in Q2 2025 to a low of $2.1 million in Q2 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $3.0 million (2023), against an average of $3.2 million.
• Across the five-year window, Accumulated Depreciation & Amortization jumped 52.7% in 2021 and gained 15.8% in 2022, its largest moves.
• KalVista Pharmaceuticals' Accumulated Depreciation & Amortization stood at $2.1 million in 2021, then advanced by 15.8% to $2.4 million in 2022, then gained by 22.28% to $3.0 million in 2023, then climbed by 25.49% to $3.7 million in 2024, then grew by 27.88% to $4.7 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $4.7 million (Q2 2025), $3.7 million (Q2 2024), and $3.0 million (Q2 2023), per Business Quant data.